Business Description
Dynavax Technologies Corp
NAICS : 325412
SIC : 2834
ISIN : US2681582019
Share Class Description:
DVAX: Ordinary SharesDescription
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.64 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.45 | |||||
| Debt-to-EBITDA | 2.06 | |||||
| Interest Coverage | 15.96 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 3.64 | |||||
| Beneish M-Score | 2.23 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 114 | |||||
| 3-Year Book Growth Rate | 258.3 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 85.86 | |||||
| 9-Day RSI | 72.78 | |||||
| 14-Day RSI | 65.27 | |||||
| 6-1 Month Momentum % | 48.22 | |||||
| 12-1 Month Momentum % | 39.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 17.78 | |||||
| Quick Ratio | 16.59 | |||||
| Cash Ratio | 15.19 | |||||
| Days Inventory | 151.54 | |||||
| Days Sales Outstanding | 94.09 | |||||
| Days Payable | 9.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 63.63 | |||||
| Operating Margin % | 22.46 | |||||
| Net Margin % | 24.08 | |||||
| ROE % | 20.91 | |||||
| ROA % | 11.26 | |||||
| ROIC % | 39.82 | |||||
| ROC (Joel Greenblatt) % | 73.05 | |||||
| ROCE % | 14.73 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 20.81 | |||||
| Forward PE Ratio | 215.53 | |||||
| PE Ratio without NRI | 20.81 | |||||
| Price-to-Owner-Earnings | 34.18 | |||||
| PS Ratio | 4.9 | |||||
| PB Ratio | 3.34 | |||||
| Price-to-Tangible-Book | 3.36 | |||||
| Price-to-Free-Cash-Flow | 14.99 | |||||
| Price-to-Operating-Cash-Flow | 14.51 | |||||
| EV-to-EBIT | 12.47 | |||||
| EV-to-EBITDA | 11.83 | |||||
| EV-to-Revenue | 3.23 | |||||
| EV-to-Forward-Revenue | 5.7 | |||||
| EV-to-FCF | 10.06 | |||||
| Price-to-Projected-FCF | 5.24 | |||||
| Price-to-Median-PS-Value | 0.19 | |||||
| Price-to-Graham-Number | 1.76 | |||||
| Price-to-Net-Current-Asset-Value | 4.41 | |||||
| Price-to-Net-Cash | 6 | |||||
| Earnings Yield (Greenblatt) % | 8.02 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DVAX
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dynavax Technologies Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 459.401 | ||
| EPS (TTM) ($) | 0.72 | ||
| Beta | 1.74 | ||
| Volatility % | 29.3 | ||
| 14-Day RSI | 65.27 | ||
| 14-Day ATR ($) | 0.376716 | ||
| 20-Day SMA ($) | 13.9635 | ||
| 12-1 Month Momentum % | 39.27 | ||
| 52-Week Range ($) | 9.42 - 15.12 | ||
| Shares Outstanding (Mil) | 128.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dynavax Technologies Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dynavax Technologies Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Dynavax Technologies Corp Frequently Asked Questions
What is Dynavax Technologies Corp(DVAX)'s stock price today?
The current price of DVAX is $15.00. The 52 week high of DVAX is $15.12 and 52 week low is $9.42.
When is next earnings date of Dynavax Technologies Corp(DVAX)?
The next earnings date of Dynavax Technologies Corp(DVAX) is 2023-11-03 Est..
Does Dynavax Technologies Corp(DVAX) pay dividends? If so, how much?
Dynavax Technologies Corp(DVAX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers